| Sep 27 |
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
|
| Sep 27 |
FDA, after delay, clears Regeneron and Sanofi drug for COPD
|
| Sep 26 |
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
|
| Sep 26 |
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
|
| Sep 25 |
Amgen Stock Falls on Disappointing Drug Data
|
| Sep 25 |
Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors
|
| Sep 24 |
US Equity Indexes Rise as Sliding Consumer Confidence Undermines Bowman's Call for Policy Caution
|
| Sep 24 |
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
|
| Sep 24 |
Regeneron slump continues as analysts turn more cautious
|
| Sep 24 |
HRMY vs. REGN: Which Stock Should Value Investors Buy Now?
|
